Gene-STEPS: Shortening Time of Evaluation in Paediatric Epilepsy Services

Epilepsy Clinical Trial

— Gene-STEPS  

Official title:

Gene-STEPS: Shortening Time of Evaluation in Paediatric Epilepsy Services: a Multi-centre Prospective Evaluation of the Impact of Early Genetic Diagnosis on Patient Outcomes

Clinical Trial Details — Status: Recruiting

Administrative data

• NCT number: NCT06082999
• Other study ID #: 20NM24
• Status: Recruiting
• Start date: September 1, 2021
• Est. completion date: December 2025

Study information

• Verified date: August 2023
• Source: Great Ormond Street Hospital for Children NHS Foundation Trust
• Contact: Amy McTague, Dr
• Phone: 02039783678
• Email: a.mctague[@]ucl.ac.uk
• Is FDA regulated: No
• Study type: Observational

Clinical Trial Summary

Overall, this observational cohort study aims too: 1. Implement rapid trio WGS for all children presenting to our health systems with epilepsy onset under 12 months of age. 2. Utilize electronic healthcare records and research databases to unite phenotypic and genomic data and to create a "virtual" registry across all institutions that will promote ongoing discovery. 3. Assess the impact of early genetic diagnosis on epilepsy, developmental, and health economic outcomes through formal longitudinal assessments of all children enrolled.

Description:

In the past decade, the genomic revolution has led to the identification of underlying genetic aetiologies for childhood epilepsy, in the form of monogenic disorders affecting ion channels, neurotransmitter receptors, synaptic proteins, and other families of proteins. In a growing number of cases, the specific genetic diagnosis informs prognosis and genetic counselling, leads to the opportunity to participate in natural history studies, and even to changes in treatment that, to date anecdotally, may change outcomes in seizures and in neurodevelopment. However, a major challenge in clinical practice is that early intervention requires early diagnosis. Currently the diagnostic odyssey in early-onset epilepsy is long and arduous for patients and their families. The timing and nature of genetic testing for such patients varies widely within and across countries and institutions. Our collective expertise includes epilepsy genetics research, genomic research, clinical epilepsy, clinical trials, and team science across four leading paediatric institutions in the IPCHiP Consortium: Boston Children's Hospital (US), Great Ormond Street Hospital and UCL Great Ormond Street Institute of Child Health (UK), Royal Children's Hospital Melbourne and Murdoch Children's Research Institute (Australia), and The Hospital for Sick Children ("Sick Kids", Canada). Each of our institutions has a proven track record of discovery and translation to patients, and our combined efforts in epilepsy will set a new standard for multi-institutional research, data sharing, and improvement. To investigate our hypothesis that rapid genetic diagnosis and tailored management could improve outcomes, we propose a novel approach to streamline and accelerate diagnostics in these severely affected children. Overall, this observational cohort study aims too: 1. Implement rapid trio WGS for all children presenting to our health systems with epilepsy onset under 12 months of age. 2. Utilize electronic healthcare records and research databases to unite phenotypic and genomic data and to create a "virtual" registry across all institutions that will promote ongoing discovery. 3. Assess the impact of early genetic diagnosis on epilepsy, developmental, and health economic outcomes through formal longitudinal assessments of all children enrolled.

Recruitment information / eligibility

• Status: Recruiting
• Enrollment: 300
• Est. completion date: December 2025
• Est. primary completion date: December 2025
• Accepts healthy volunteers: No
• Gender: All
• Age group: N/A to 12 Months

Eligibility

Inclusion Criteria:

• Children under 12 months of age presenting with epilepsy.

Exclusion Criteria:

• Simple febrile seizures.
• Acute or remote symptomatic seizures due to sepsis, haemorrhage, cerebral infarction, hypoxic ischaemic encephalopathy or non-accidental injury.
• Structural malformations of the brain where the likely genetic cause is known such as tuberous sclerosis or lissencephaly.

Related Conditions & MeSH terms

• Epilepsy

Locations

Country	Name	City	State
Australia	Murdoch Childrens Research Institute	Parkville	Victoria
Canada	The Hospital for Sick Children	Toronto	Ontario
United Kingdom	UCL Great Ormond Street Institute of Child Health	London
United States	Boston Children's Hospital	Boston	Massachusetts

Sponsors (4)

Lead Sponsor	Collaborator
Great Ormond Street Hospital for Children NHS Foundation Trust	Boston Children's Hospital, Murdoch Childrens Research Institute, The Hospital for Sick Children

Countries where clinical trial is conducted

United States,  Australia,  Canada,  United Kingdom, 

Outcome

Type	Measure	Description	Time frame	Safety issue
Primary	Feasibility of rapid genome sequencing in infantile epilepsy	Feasibility is measured as the turnaround for participants, from both sample collection and seizure onset to GS result.	Within three weeks of sample collection
Primary	The Diagnostic Yield of rapid genome sequencing in infantile epilepsy	The diagnostic yield is measured as the number of patients who receive a genetic diagnosis.	Within three weeks of sample collection
Primary	The immediate clinical utility of rapid genome sequencing in infantile epilepsy	Clinical utility is measured as actual influence on treatment, potential for precision therapy, additional investigation indicated or avoided, additional prognostic information, influence on goals of care, or influence on genetic counselling (beyond recurrence risk). These are measured using The Clinician-reported Genetic testing Utility InDEx (C-GUIDE; Hayeems et al., 2022), as well as clinical data abstracted from health care records.	Within one month of genetic result
Secondary	The impact of early genetic diagnosis on developmental outcomes - Bayley 4 - Scales of Infant and Toddler Development.	Bayley-4 items are scored 2 points for mastery of skill, 1 point for emerging skill and 0 points if skill is not present. Higher scores are, therefore, indicative of more advanced developmental abilities. Subtest standard scores range from 1 to 19, have a mean of 10 and a standard deviation of 3 (Bayley & Alyward, 2019).	At Recruitment, 12 and 30 months chronological age
Secondary	The impact of early genetic diagnosis on developmental outcomes - Vineland Adaptive Behaviour Scales, Third Edition.	The Vineland 3 generates five major domain composite scores: communication, daily living skills, socialisation, adaptive behaviour composite and motor skills, as well as a maladaptive score. Domain scores greater than or equal to 86 are considered adequate or above adequate. Domain scores less than or equal to 85 are considered moderately low-to-low, and indicate the patient has a significant skill deficit when compared with similarly aged peers. This is especially true for a domain score below 70. Maladaptive behavior scores up to 17 are considered average, scores of 18 to 20 are considered elevated and scores greater than 21 are considered clinically significant indicating a need for treatment intervention.	At Recruitment, 12 and 30 months chronological age
Secondary	The impact of early genetic diagnosis on developmental outcomes - Gross Motor Function Classification System (GMFCS)	The GMFCS is a standardised classification of functional motor abilities in children with cerebral palsy. Children are assigned a GMFCS level of 1-V according to motor functioning abilities. Level I represents the highest level of gross motor function and level V the lowest.	At Recruitment, 12 and 30 months chronological age
Secondary	The impact of early genetic diagnosis on developmental outcomes - Paediatric Quality of Life Scale (PedsQL™) Infant Scales	The PedsQL™ Infant Scales are a generic health related quality of life instrument specifically for healthy and ill infants ages 1-24 months. The PedsQL Infant Scales encompasses 5 scales: Physical functioning, physical symptoms, emotional functioning, social functioning and cognitive functioning. The Total Scale Score is computed as the sum of all items on the PedsQL™. Items are reversed scored and linearly transformed to a 0-100 scale, so that higher scores indicate better HRQOL.	At Recruitment, 12 and 30 months chronological age
Secondary	The impact of early genetic diagnosis on developmental outcomes - Parenting Stress Index, Fourth Edition Short Form	The PSI-4 SF has thirty-six items are divided into three domains: Parental Distress (PD), Parent-Child Dysfunctional Interaction (P-CDI), and Difficult Child (DC), which combine to form a Total Stress scale. Percentile scoring: Between 16%-84% = Normal ranges of stress. Between 85%-89% = High levels of stress. Greater than or equal to 90% = Clinically significant.	At Recruitment, 12 and 30 months chronological age
Secondary	The impact of early genetic diagnosis on epilepsy	Clinical Dataset & Seizure diary 4 weeks prior to visit	12 months and 30 months chronological age. The clinical dataset will also be retrieved at recruitment.
Secondary	The views and experiences of parents offered rapid genomic sequencing for diagnosis of their child	Qualitative interviews will be utilised to ascertain parents experiences of receiving the result, the impact of the result, and their hopes and concerns for the future. Parents who decline to participate will be asked about their decision not to take part in the study and have genome sequencing and suggestions for improving counselling and information.	For participating parents: 3-4 weeks and then 6 months after receiving GS result. For non-participating parents: 3 months after deciding not to participate.